US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A drug portfolio — 38 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
Chiesi Farmaceutici S.p.A pipeline
Portfolio lens on 38 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chiesi Farmaceutici S.p.A drug portfolio — 38 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
afamelanotide
Dermatologicals (D02)US regulatory status: approved. Molecular target: Melanocyte-stimulating hormone receptor.
- Target
- Melanocyte-stimulating hormone receptor
- Mechanism
- Melanocortin receptor 1 agonist
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
dodecafluoropentane
Various (V08)Various (V08) compound in Chiesi Farmaceutici S.p.A's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
pegunigalsidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Chiesi Farmaceutici S.p.A's portfolio. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Chiesi Farmaceutici S.p.A's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
repaglinide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
roflumilast
Respiratory system (R03)US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
Development asset linked to Chiesi Farmaceutici S.p.A in public FDA and regional records.
-
ulipristal acetate
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor modulator